

## PRESS RELEASE

NeuroVive Pharmaceutical AB (publ)  
556595-6538



23 May, 2016

---

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS.

### **Updated timeline for conversion of NeuroVive's BTUs into shares and warrants**

*NeuroVive Pharmaceutical AB (publ) announces that registration of the preferential rights issue totaling SEK 94.4 m has now been completed, and provides an updated timeline for the conversion of NeuroVive's BTUs into shares and warrants.*

The last day of trading in BTUs will be 24 May 2016, and the first day of trading in new shares and warrants (series 2016/2017:1 and series 2016/2017:2) will be 26 May 2016. The conversion of BTUs in the Euroclear system will be effected on 26 May 2016, and the new shares and warrants will appear in the relevant VP accounts on 30 May 2016.

After the completion of the new issue, NeuroVive's share capital amounts to SEK 2,472,932.25. The total number of shares after registration is 49,458,645.

#### **Advisors**

Stockholm Corporate Finance AB acted as financial advisor and Advokatfirman Lindahl KB acted as legal advisor to the company in connection with the new issue. Aqurat Fondkommission AB acted as issuing institution in connection with the new issue and Laika Consulting was responsible for IR and marketing.

#### **About NeuroVive**

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive's portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive's shares are listed on Nasdaq, Stockholm, Sweden.

#### **For investor relations and media questions, please contact:**

Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or [ir@neurovive.com](mailto:ir@neurovive.com)

#### **NeuroVive Pharmaceutical AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48

[info@neurovive.com](mailto:info@neurovive.com), [www.neurovive.com](http://www.neurovive.com)

## PRESS RELEASE

NeuroVive Pharmaceutical AB (publ)  
556595-6538



23 May, 2016

---

*NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 23 May 2016, at 17.15 CET.*

### IMPORTANT INFORMATION

Publication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and the people in jurisdictions where this press release has been made public or distributed should inform themselves and follow such legal restrictions. This press release does not contain and does not constitute or form part of an invitation to acquire or subscribe or a solicitation of any offer to buy or subscribe for shares or other securities in NeuroVive.

This press release may not be published or distributed, directly or indirectly, in or into the US, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other jurisdiction where such distribution would be prohibited by applicable law. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 or applicable laws of other jurisdictions.